Kamada Plans Three More Biosimilar Launches In Israel

Post Approval, Company Expects Sales Of $5m-$7m From The Candidates

 
• By Akriti Seth
  
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products